Safety and Pharmacodynamics of SEL-212 (Pegsiticase + SEL-110) in Subjects With Elevated Blood Uric Acid Levels
Status: | Recruiting |
---|---|
Conditions: | Gout |
Therapuetic Areas: | Rheumatology |
Healthy: | No |
Age Range: | 21 - 70 |
Updated: | 4/21/2016 |
Start Date: | December 2015 |
End Date: | July 2016 |
Contact: | Earl Sands, MD |
Email: | ssands@selectabio.com |
Phone: | 617-923-1400 |
A Phase I Single Ascending Dose Safety, Pharmacokinetic and Pharmacodynamics Study of SEL-212 in Subjects With Elevated Blood Uric Acid
This Study will first evaluate the safety and pharmacokinetics of a single intravenous dose
of SEL-110, a nanoparticle containing rapamycin, in subjects with elevated blood uric acid
levels. This will be followed, in separate subjects, by evaluation of the safety,
pharmacokinetics, pharmacodynamics and immunogenicity of a single intravenous dose of
SEL-212, SEL-037 (pegsiticase) plus SEL-110, in subjects with elevated blood uric acid
levels. Uricase is an enzyme that converts uric acid to the readily soluble allantoin that
is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs)
from forming.
of SEL-110, a nanoparticle containing rapamycin, in subjects with elevated blood uric acid
levels. This will be followed, in separate subjects, by evaluation of the safety,
pharmacokinetics, pharmacodynamics and immunogenicity of a single intravenous dose of
SEL-212, SEL-037 (pegsiticase) plus SEL-110, in subjects with elevated blood uric acid
levels. Uricase is an enzyme that converts uric acid to the readily soluble allantoin that
is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs)
from forming.
This Study will first evaluate the safety and pharmacokinetics of a single intravenous dose
of SEL-110, a nanoparticle containing rapamycin, in subjects with elevated blood uric acid
levels. This will be followed, in separate subjects, by evaluation of the safety,
pharmacokinetics, pharmacodynamics and immunogenicity of a single intravenous dose of
SEL-212, SEL-037 (pegsiticase) plus SEL-110, in subjects with elevated blood uric acid
levels. Uricase is an enzyme that converts uric acid to the readily soluble allantoin that
is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs)
from forming. Cohorts of subjects in the SEL-110 only arms of the study will be given a
single, ascending intravenous dose of SEL-110 and then monitored for safety and rapamycin
levels (pharmacokinetics) over 30 days. Cohorts of subjects in the SEL-212 arms of the study
will be given a single, ascending intravenous dose of SEL-110 with a fixed dose of SEL-037
and then monitored for safety, rapamycin levels, SEL-037 levels, uric acid levels and
anti-drug-antibodies (ADAs) to SEL-037 for 30 days. One additional control group with
receive a single intravenous infusion of SEL-037 at a fixed dose and then monitored for
safety, SEL-037 levels, uric acid levels and anti-drug-antibodies (ADAs) to SEL-037 for 30
days
of SEL-110, a nanoparticle containing rapamycin, in subjects with elevated blood uric acid
levels. This will be followed, in separate subjects, by evaluation of the safety,
pharmacokinetics, pharmacodynamics and immunogenicity of a single intravenous dose of
SEL-212, SEL-037 (pegsiticase) plus SEL-110, in subjects with elevated blood uric acid
levels. Uricase is an enzyme that converts uric acid to the readily soluble allantoin that
is then excreted and SEL-110 is designed to prevent unwanted anti-drug-antibodies (ADAs)
from forming. Cohorts of subjects in the SEL-110 only arms of the study will be given a
single, ascending intravenous dose of SEL-110 and then monitored for safety and rapamycin
levels (pharmacokinetics) over 30 days. Cohorts of subjects in the SEL-212 arms of the study
will be given a single, ascending intravenous dose of SEL-110 with a fixed dose of SEL-037
and then monitored for safety, rapamycin levels, SEL-037 levels, uric acid levels and
anti-drug-antibodies (ADAs) to SEL-037 for 30 days. One additional control group with
receive a single intravenous infusion of SEL-037 at a fixed dose and then monitored for
safety, SEL-037 levels, uric acid levels and anti-drug-antibodies (ADAs) to SEL-037 for 30
days
Inclusion Criteria:
- Male or female subjects ages 21 to 70 inclusive. Female subjects must be of
non-childbearing potential;
- Has at the screening visit a serum uric acid ≥ 6 mg/dL, with or without a history of
gout;
- The use of allopurinol, febuxostat (Uloric®), or probenecid as uric acid-lowering
therapy is permissible if dosing has been stable for at least the month prior to the
screening visit;
- Has adequate venous access and able to receive IV therapy;
- Evidence of a personally signed and dated informed consent document indicating that
subject has been informed of all pertinent aspects of the study;
Exclusion Criteria:
- Prior exposure to any experimental or marketed uricase (for arms receiving SEL-037 or
SEL-212);
- History of any allergy to pegylated products;
- Glucose-6-phosphate dehydrogenase deficiency or known catalase deficiency;
- History of hematological or autoimmune disorders, is immunosuppressed or
immunocompromised;
- Presently taking a drug classified as CYP3A4 inducer or inhibitor;
- Has participated in a clinical trial within 30 days of the Screening;
We found this trial at
6
sites
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
5055 South Orange Ave Orlando FL 32909
Orlando, Florida 32806
Orlando, Florida 32806
407-240-7878
![Orlando Clinical Research Center](/wp-content/uploads/logos/ocrclogo.gif)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)
Click here to add this to my saved trials
![](https://www.clinicaltrialsgps.com/wp-content/themes/GPS/media//img/tooltip-arrow.png)